Diagnostic value of additional Ga-PSMA-PET before Ra-dichloride therapy in patients with metastatic prostate carcinoma.

PURPOSE

Medical imaging plays an important role in selecting patients with metastatic castration-resistant prostate cancer for Ra-dichloride therapy of bone metastases. The purpose of this study was to investigate whether Ga-PSMA-PET has incremental value over conventional imaging for selecting patients suitable for Ra-dichloride therapy.

METHODS

In 27 consecutive patients referred for Ra-dichloride therapy additional Ga-PSMA-PET/CT was performed and tracer distribution was evaluated systematically with respect to the detection of visceral metastases and bone metastases with inadequate uptake on bone scintigraphy.

RESULTS

In 4 patients (15 %) Ga-PSMA-PET revealed previously unknown visceral metastases (3 liver, 1 adrenal gland), which changed the therapeutic decision in 2 cases. PET revealed more extended tumour involvement in the bone compared to bone scintigraphy in 9 patients (33 %). In 3 of these, the mismatch was extensive enough to question suitability for Ra-dichloride therapy.

CONCLUSIONS

Additional Ga-PSMA-PET as a gatekeeper between conventional staging and Ra-dichloride therapy can provide valuable additional information with regard to visceral metastases and tumour manifestations without adequate bone mineral turnover. It may lead to a change in therapeutic management in a significant number of patients and should therefore be considered in future clinical trials.